INVO Fertility, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INVO Fertility, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.53M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $3.02M | Apr 30, 2025 |
| FY2020 | Dec 31, 2020 | $1.04M | Mar 30, 2021 |
| FY2020 | Dec 31, 2019 | $1.48M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $494.4K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $282.1K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $50.9K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $11.7K | Apr 20, 2017 |
| FY2015 | Sep 30, 2015 | $2.5K | Mar 17, 2017 |
| FY2015 | Jun 30, 2015 | $5.6K | Mar 17, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.56M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $3.02M | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | $822.2K | Nov 19, 2024 |
| FY2022 | Dec 31, 2021 | $4.16M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.04M | Mar 31, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $490.7K | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $4.02M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $948.5K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.34M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $404.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $230.2K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $35.8K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $3.9K | Apr 20, 2017 |
| FY2015 | Sep 30, 2015 | ($1.9K) | Mar 17, 2017 |
| FY2015 | Jun 30, 2015 | $6.0K | Mar 17, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($9.10M) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | ($8.03M) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | ($10.89M) | Nov 19, 2024 |
| FY2022 | Dec 31, 2021 | ($6.65M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($8.35M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.17M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($3.08M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($702.2K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($2.12M) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | ($4.96M) | Apr 20, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($8.13M) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | ($6.77M) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | ($10.63M) | Nov 19, 2024 |
| FY2022 | Dec 31, 2021 | ($5.22M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($5.51M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.79M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($2.63M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($640.4K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($2.11M) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | ($595.1K) | Apr 20, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $489.7K | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $165.9K | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | $544.0K | Nov 19, 2024 |
| FY2022 | Dec 31, 2021 | $216.4K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $398.4K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 30, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $9.08M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $7.49M | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | $9.98M | Nov 19, 2024 |
| FY2022 | Dec 31, 2021 | $9.02M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $6.07M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.13M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $3.04M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $870.6K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $2.15M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $599.0K | Apr 20, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($2.97M) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | ($4.76M) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | ($6.60M) | Nov 19, 2024 |
| FY2022 | Dec 31, 2021 | ($6.03M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($4.78M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.37M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($653.0K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($181.3K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($323.9K) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | ($151.6K) | Apr 20, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $183.7K | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $444.7K | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | $10.8K | Nov 19, 2024 |
| FY2022 | Dec 31, 2021 | $415.7K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $49.3K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $64.8K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $19.4K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $15.7K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Apr 20, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $46.45M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $18.51M | Apr 30, 2025 |
| FY2023 | Sep 30, 2023 | $17.04M | Nov 19, 2024 |
| FY2023 | Jun 30, 2023 | $4.89M | Nov 19, 2024 |
| FY2023 | Mar 21, 2023 | $5.78M | Nov 19, 2024 |
| FY2023 | Dec 31, 2022 | $3.71M | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $4.27M | Nov 19, 2024 |
| FY2023 | Jun 30, 2022 | $5.99M | Nov 19, 2024 |
| FY2023 | Mar 31, 2022 | $8.07M | Nov 19, 2024 |
| FY2023 | Dec 31, 2021 | $9.99M | Nov 19, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $26.24M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $17.61M | Apr 30, 2025 |
| FY2023 | Sep 30, 2023 | $16.67M | Nov 19, 2024 |
| FY2023 | Jun 30, 2023 | $6.60M | Nov 19, 2024 |
| FY2023 | Mar 21, 2023 | $5.69M | Nov 19, 2024 |
| FY2023 | Dec 31, 2022 | $4.69M | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $2.98M | Nov 19, 2024 |
| FY2023 | Jun 30, 2022 | $2.64M | Nov 19, 2024 |
| FY2023 | Mar 31, 2022 | $2.48M | Nov 19, 2024 |
| FY2023 | Dec 31, 2021 | $2.68M | Nov 19, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $12.75M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $892.8K | Apr 30, 2025 |
| FY2024 | Dec 31, 2022 | ($977.6K) | Apr 30, 2025 |
| FY2023 | Dec 31, 2021 | $7.31M | Nov 19, 2024 |
| FY2020 | Dec 31, 2020 | $5.74M | Mar 30, 2021 |
| FY2020 | Dec 31, 2019 | ($3.71M) | Mar 30, 2021 |
| FY2020 | Dec 31, 2018 | ($2.72M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | ($4.99M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($4.62M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2015 | ($3.76M) | Mar 29, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $23.54M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $5.88M | Apr 30, 2025 |
| FY2023 | Aug 10, 2023 | $5.88M | Nov 19, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($67.16M) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | ($57.82M) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | ($49.78M) | Nov 19, 2024 |
| FY2022 | Dec 31, 2021 | ($38.89M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($32.24M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($23.89M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($21.72M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($18.65M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($17.94M) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | ($15.82M) | Apr 20, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $5.68M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $10.10M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.24M | Mar 30, 2021 |
| FY2020 | Dec 31, 2018 | $212.2K | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $25.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $152.4K | Apr 16, 2019 |
| FY2017 | Dec 31, 2015 | $492.0K | Mar 29, 2018 |
| FY2015 | Sep 30, 2015 | $114.6K | Mar 17, 2017 |
| FY2015 | Jun 30, 2015 | $79.6K | Mar 17, 2017 |
| FY2015 | Mar 31, 2015 | $24.5K | Mar 17, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (30) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | (67) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | (17) | Nov 19, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Apr 20, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (30) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | (67) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | (17) | Nov 19, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Apr 20, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 373,021 | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | 207,711 | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | 608,611 | Nov 19, 2024 |
| FY2022 | Dec 31, 2021 | 11.93M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 9.64M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 4.88M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 154.29M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 142.13M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 140.60M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | 137.09M | Apr 20, 2017 |